Seneschal Advisors
SMMT icon

Seneschal Advisors’s Summit Therapeutics SMMT Stock Holding History

Seneschal Advisors’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-1
Closed -$15 – 644
2026
Q2 		$15 Hold
1
– – ﹤0.01% 596
2026
Q1 		$19 Sell
1
-1
-50% -$16 ﹤0.01% 593
2025
Q4 		$35 Hold
2
– – ﹤0.01% 588
2025
Q3 		$42 Buy
+2
New +$49 ﹤0.01% 585

Other funds holding SMMT

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

Seneschal Advisors's SMMT Position: Q3 2026 in Review

Seneschal Advisors sold out of Summit Therapeutics (SMMT) in Q3 2026, closing a stake of 1 share — an estimated $15 sold.

Seneschal Advisors first reported a position in SMMT in Q3 2025 and held it in 4 quarters. The position peaked at $42 in Q3 2025. 211 funds tracked by Wall St. Rank hold SMMT as of Q3 2026.

  • Seneschal Advisors reported no remaining Summit Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Seneschal Advisors sold 1 Summit Therapeutics share in Q3 2026, an estimated $15.
  • Seneschal Advisors first reported a position in Summit Therapeutics in Q3 2025 and held it in 4 quarters.
  • Seneschal Advisors's Summit Therapeutics position peaked at $42 in Q3 2025.
  • 211 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2026.

Based on Seneschal Advisors's 13F filing for Q3 2026, filed 13 Nov 2026.